Lastly, pro-drugs, such as DRP104, target GLS-1 in tumors and cause CD8+ T cell-dependent tumor regression (94) Such approaches could potentially unleash the immune cells in destroying cancer cells in the TME. The gene discussed is CD8A; the disease is neoplasm.